AJP - Lung Cellular and Molecular Physiology, Vol 262, Issue 3 286-L291, Copyright © 1992 by American Physiological Society

ARTICLES

Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants

W. Seeger, A. Gunther and C. Thede
Department of Internal Medicine, Justus-Liebig-University Giessen, Federal Republic of Germany.

Inhibition of surfactant function by plasma-derived proteins is assumed to occur under conditions of alveolar protein leakage. We investigated surface properties and sensitivity to the inhibitory capacity of fibrinogen (Fbg) of artificial surfactants in a pulsating-bubble surfactometer. Phospholipid-fatty acid mixtures (PLM) with or without hydrophobic apoproteins [natural bovine surfactant proteins (SP) B and C, recombinant human SP-C] were used. Without Fbg, all apoprotein-based surfactants exhibited rapid absorption facilities and reduced surface tension to near zero values under dynamic compression. Fbg caused a dose-dependent reduction of adsorption kinetics and dynamic surface tension-lowering properties of all surfactant preparations, but there was a marked rank order of "Fbg sensitivity": PLM without apoprotein being the most sensitive and SP-B-based PLM the least. Fbg sensitivity of recombinant SP-C-based PLM could be lowered dose dependently by adding small amounts of SP-B. For further support of a putative role of SP-B in resistance to Fbg inhibition, calf lung surfactant extract was incubated with monoclonal antibody against SP-B. Without Fbg, anti-SP-B had little influence. However, sensitivity to the inhibitory effect of Fbg was markedly and dose dependently increased by anti-SP-B but not by control immunoglobulin. We conclude that SP-B-based surfactant preparations display markedly lower susceptibility to Fbg inhibition than SP-C combinants.

This article has been cited by other articles:

				Z. Wang, J. E. Baatz, B. A. Holm, and R. H. Notter Content-dependent activity of lung surfactant protein B in mixtures with lipids Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L897 - L906. [Abstract] [Full Text] [PDF]

				R. Schmidt, U. Meier, P. Markart, F. Grimminger, H. G. Velcovsky, H. Morr, W. Seeger, and A. Gunther Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L1079 - L1085. [Abstract] [Full Text] [PDF]

				R. SCHMIDT, U. MEIER, M. YABUT-PEREZ, D. WALMRATH, F. GRIMMINGER, W. SEEGER, and A. GÜNTHER Alteration of Fatty Acid Profiles in Different Pulmonary Surfactant Phospholipids in Acute Respiratory Distress Syndrome and Severe Pneumonia Am. J. Respir. Crit. Care Med., January 1, 2001; 163(1): 95 - 100. [Abstract] [Full Text]

				A. GÜNTHER, R. SCHMIDT, A. FEUSTEL, U. MEIER, C. PUCKER, M. ERMERT, and W. SEEGER Surfactant Subtype Conversion Is Related to Loss of Surfactant Apoprotein B and Surface Activity in Large Surfactant Aggregates . Experimental and Clinical Studies Am. J. Respir. Crit. Care Med., January 1, 1999; 159(1): 244 - 251. [Abstract] [Full Text]

				I. Y. Haddad, B. Nieves-Cruz, and S. Matalon Inhibition of surfactant function by copper-zinc superoxide dismutase (CuZn-SOD) J Appl Physiol, November 1, 1997; 83(5): 1545 - 1550. [Abstract] [Full Text] [PDF]